\-\ Texto\\:\\ \ \(0\)\
\-\ no\\ visible\\ abnormality\\ of\\ the\\ eyelid\\/puncta\\/eye\\/orbit\\;\\ no\\ visible\\ obstruction\\ in\\ the\\ nasopharynx\ \(0\)\
\-\ therapeutic\\ dilation\\ of\\ duct\ \(0\)\
\-\ mild\\ narrowing\\ in\\ the\\ region\\ of\\ the\\ valve\\ of\\ krause\ \(0\)\
\-\ nasolacrimal\\ duct\\ stenosis\\ at\\ the\\ level\\ of\\ the\\ valve\\ of\\ krause\ \(0\)\
\-\ congential\\ nasolacrimal\\ duct\\ stenosis\ \(0\)\
\-\ acquired\\ nasolacrimal\\ duct\\ stenosis\ \(0\)\
\-\ chronic\\ overflow\\ of\\ tears\\ from\\ right\\ orbit\ \(0\)\
\-\ acquired\\ nasolacrimal\\ drainage\\ obstructions\\ may\\ be\\ related\\ to\\ infection\\ \\(numerous\\ bacterial\\/viral\\/parasitic\\ causes\\)\\,\\ inflammation\\/scarring\\ \\(wegener\\'s\\ granulomatosis\\,\\ sarcoidosis\\,\\ radiation\\)\\,\\ medications\\ \\(chemotherapy\\)\\,\\ congenital\\ narrowing\\,\\ tumors\\ \\(scc\\)\\,\\ or\\ trauma\\.\\ \\ occasionally\\,\\ small\\ nasolacrimal\\ duct\\ stones\\ may\\ be\\ found\\ blocking\\ the\\ duct\\.\ \(0\)\
\-\ of\\ interest\\,\\ the\\ use\\ of\\ i\\(131\\)\\ for\\ thyroid\\ carcinoma\\ is\\ associated\\ with\\ a\\ an\\ overall\\ 4\\.6\\%\\ incidence\\ of\\ documented\\ or\\ suspected\\ obstruction\\.\\ \\ \ \(0\)\
\-\ the\\ cause\\ of\\ the\\ narrowing\\ in\\ our\\ patient\\ was\\ unknown\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ nasolacrimal\\:\\ 0\\.22152834459089976\ \(0\)\
\-\ duct\\:\\ 0\\.15990524995981986\ \(0\)\
\-\ krause\\:\\ 0\\.11993902617641494\ \(0\)\
\-\ narrowing\\:\\ 0\\.06992748355408157\ \(0\)\
\-\ stenosis\\:\\ 0\\.06831547515982381\ \(0\)\
\-\ acquired\\:\\ 0\\.062332134957404604\ \(0\)\
\-\ eyelid\\/puncta\\/eye\\/orbit\\:\\ 0\\.05996951308820747\ \(0\)\
\-\ overflow\\:\\ 0\\.05996951308820747\ \(0\)\
\-\ bacterial\\/viral\\/parasitic\\:\\ 0\\.05996951308820747\ \(0\)\
\-\ valve\\:\\ 0\\.05812549172376183\ \(0\)\
\-\ inflammation\\/scarring\\:\\ 0\\.05525422614562281\ \(0\)\
\-\ visible\\:\\ 0\\.055031752374161\ \(0\)\
\-\ blocking\\:\\ 0\\.04778067316148601\ \(0\)\
\-\ obstructions\\:\\ 0\\.04673202908102847\ \(0\)\
\-\ congential\\:\\ 0\\.045823652260453485\ \(0\)\
\-\ 4\\.6\\:\\ 0\\.04502240711993386\ \(0\)\
\-\ interest\\:\\ 0\\.04252087800343511\ \(0\)\
\-\ 131\\:\\ 0\\.04252087800343511\ \(0\)\
\-\ scc\\:\\ 0\\.04154740287662781\ \(0\)\
\-\ obstruction\\:\\ 0\\.040998640116863064\ \(0\)\
\-\ nasopharynx\\:\\ 0\\.0399393159510208\ \(0\)\
\-\ wegener\\:\\ 0\\.03706273873455798\ \(0\)\
\-\ granulomatosis\\:\\ 0\\.03639307837528416\ \(0\)\
\-\ documented\\:\\ 0\\.034875095033010624\ \(0\)\
\-\ tears\\:\\ 0\\.0343831177433533\ \(0\)\
\-\ therapeutic\\:\\ 0\\.03270874312063964\ \(0\)\
\-\ occasionally\\:\\ 0\\.030598845649184952\ \(0\)\
\-\ stones\\:\\ 0\\.029909372899114967\ \(0\)\
\-\ orbit\\:\\ 0\\.02928339399625611\ \(0\)\
\-\ overall\\:\\ 0\\.028919525391147363\ \(0\)\
\-\ our\\:\\ 0\\.027632164849388664\ \(0\)\
\-\ dilation\\:\\ 0\\.027401542048873826\ \(0\)\
\-\ incidence\\:\\ 0\\.02665087499330331\ \(0\)\
\-\ sarcoidosis\\:\\ 0\\.026256403852824742\ \(0\)\
\-\ numerous\\:\\ 0\\.026067427226246\ \(0\)\
\-\ medications\\:\\ 0\\.025929062027354007\ \(0\)\
\-\ may\\:\\ 0\\.025501066243511887\ \(0\)\
\-\ suspected\\:\\ 0\\.02503210875453222\ \(0\)\
\-\ \\(\\:\\ 0\\.024570126742988457\ \(0\)\
\-\ drainage\\:\\ 0\\.024311370128618066\ \(0\)\
\-\ \\)\\:\\ 0\\.02426998952766344\ \(0\)\
\-\ i\\:\\ 0\\.024029351668221153\ \(0\)\
\-\ related\\:\\ 0\\.02399490743722424\ \(0\)\
\-\ thyroid\\:\\ 0\\.023825254727378984\ \(0\)\
\-\ use\\:\\ 0\\.022975776292811584\ \(0\)\
\-\ unknown\\:\\ 0\\.02268625510628916\ \(0\)\
\-\ causes\\:\\ 0\\.022629800665372866\ \(0\)\
\-\ tumors\\:\\ 0\\.021834805154221093\ \(0\)\
\-\ abnormality\\:\\ 0\\.021445972407010558\ \(0\)\
\-\ congenital\\:\\ 0\\.021259584827499577\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.020836365885312007\ \(0\)\
\-\ cause\\:\\ 0\\.01966845324185011\ \(0\)\
\-\ radiation\\:\\ 0\\.019076539112668954\ \(0\)\
\-\ found\\:\\ 0\\.018319902139130016\ \(0\)\
\-\ be\\:\\ 0\\.01792866290263849\ \(0\)\
\-\ infection\\:\\ 0\\.016898071932468076\ \(0\)\
\-\ level\\:\\ 0\\.016754347126849877\ \(0\)\
\-\ \\,\\:\\ 0\\.016574085643915555\ \(0\)\
\-\ carcinoma\\:\\ 0\\.016475698435482085\ \(0\)\
\-\ region\\:\\ 0\\.016419055967614372\ \(0\)\
\-\ chronic\\:\\ 0\\.016374079135421767\ \(0\)\
\-\ trauma\\:\\ 0\\.015898018923523327\ \(0\)\
\-\ mild\\:\\ 0\\.015307846625381883\ \(0\)\
\-\ \\;\\:\\ 0\\.013778375431650296\ \(0\)\
\-\ associated\\:\\ 0\\.013717432393929944\ \(0\)\
\-\ or\\:\\ 0\\.01362615984984636\ \(0\)\
\-\ \\%\\:\\ 0\\.013560007029564678\ \(0\)\
\-\ small\\:\\ 0\\.0133916686012321\ \(0\)\
\-\ \\'s\\:\\ 0\\.01281664366236085\ \(0\)\
\-\ no\\:\\ 0\\.011706723138827237\ \(0\)\
\-\ the\\:\\ 0\\.009404713245144613\ \(0\)\
\-\ of\\:\\ 0\\.008717971488284848\ \(0\)\
\-\ from\\:\\ 0\\.008615208933021852\ \(0\)\
\-\ in\\:\\ 0\\.0085999434722501\ \(0\)\
\-\ an\\:\\ 0\\.008038536491732856\ \(0\)\
\-\ at\\:\\ 0\\.007875939815181176\ \(0\)\
\-\ was\\:\\ 0\\.006722976341589706\ \(0\)\
\-\ right\\:\\ 0\\.00613354904156746\ \(0\)\
\-\ patient\\:\\ 0\\.0058271559926284895\ \(0\)\
\-\ for\\:\\ 0\\.004959919378521871\ \(0\)\
\-\ is\\:\\ 0\\.0038251073359505143\ \(0\)\
\-\ to\\:\\ 0\\.002905225227503308\ \(0\)\
\-\ a\\:\\ 0\\.002697957835500689\ \(0\)\
\-\ \\.\\:\\ 0\\.0009659737713563612\ \(0\)\
\-\ with\\:\\ 0\\.0007959467761216989\ \(0\)\
